Figure 1
TNFAIP8 expression is upregulated in BCC, SCC, and melanoma patient skin tissues. (A) Relative immunohistochemical TNFAIP8 expression in indicated skin cancer tissues is presented. (B) Immunohistochemical expression levels of TNFAIP8 protein from normal skin (n = 6), BCC (n = 6), H-SCC (n = 4), M-SCC (n = 4), L-SCC (n = 4), nevus (n = 6), and melanoma (n = 6) tissues were quantified using ImageJ software (https://imagej.nih.gov/ij/) and plotted. The data represent mean ± SEM from 4 to 6 skin cancer tissues. *P < 0.05 relative to normal skin tissues. (C) Expression of TNFAIP8 transcripts between cutaneous melanoma (n = 45) and melanoma precursor (n = 18) samples were analyzed and presented from the Oncomine dataset (https://www.oncomine.org/resource/login.html accessed October 17, 2020). ***P < 0.001 relatives to cutaneous melanoma tissues. (D, E) Expression of wild-type B-RAF, mutant B-RAFV600E, and TNFAIP8 in HaCaT, SK-MEL-2, A431, A375, and A2058 cells were analyzed by western blotting. Fifty micrograms of lysates from normal and skin cancer cells were immunoblotted with B-RAF, TNFAIP8, GAPDH, and β-actin antibodies. Immunoreactive bands were visualized using ECL chemiluminescence detection reagents after exposing the blots on X-ray films (D) or by scanning the blots with an Odyssey CLx Imager (E). The immunoblot scans were converted into grayscale and presented. (F) Expression of TNFAIP8 mRNA from indicated normal skin cells and skin cancer cells were analyzed by RT/qPCR as described in the “Materials and methods” section.
